FindTrial
Sign In

Certolizumab Pegol (CDP870)

BIOLOGICAL6 trials

Sponsors

UCB Pharma, UCB Pharma SA

Conditions

Crohn's DiseaseRheumatoid Arthritis

Phase 3

A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis
CompletedNCT00152386
UCB PharmaRheumatoid Arthritis
Start: 2005-02-28End: 2006-10-31Target: 950Updated: 2020-12-01
Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).
CompletedNCT00152425
UCB PharmaCrohn's Disease
Start: 2004-02-29End: 2005-05-31Target: 392Updated: 2013-09-09
A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)
CompletedNCT00152490
UCB PharmaCrohn's Disease
Start: 2003-12-31End: 2005-05-31Target: 604Updated: 2013-09-09
A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease
CompletedNCT00160706
UCB Pharma SACrohn's Disease
Start: 2004-02-29End: 2012-05-31Updated: 2018-08-07
A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]
CompletedNCT00160524
UCB Pharma SACrohn's Disease
Start: 2004-07-31End: 2012-08-31Updated: 2018-08-01
Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease
CompletedNCT00333788
UCB PharmaCrohn's Disease
Start: 2006-10-31End: 2010-04-30Updated: 2018-08-07

Related Papers

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post‐hoc analysis of clinical trials
International Journal of Rheumatic Diseases2023-05-1713 citations
Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment.
2017-12-1512 citations
Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol
Inflammatory Bowel Diseases2017-04-1424 citations
Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients.
2017-03-2810 citations
Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol.
2016-08-223 citations
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.
2016-08-016 citations
Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials.
2016-07-2517 citations
Transient Anti-Drug Antibodies and Their Impact on Markers of Inflammation: Longitudinal Data From a 7-Year Study of Certolizumab Pegol in Crohnʼs Disease Patients
The American Journal of Gastroenterology2015-10-01
Crohn’s Disease Behavior as a Risk Factor for Loss of Maintenance of Remission in Patients Treated With Certolizumab Pegol: Results From the PRECiSE 3 Study
The American Journal of Gastroenterology2014-10-011 citations
Serum Albumin as a Predictor of Long-Term Response and Remission With Certolizumab Pegol for Crohn’s Disease: Results From 7-Year Data From the PRECiSE 3 Study
The American Journal of Gastroenterology2014-10-011 citations
Predictors of Maintenance of Long-term Remission in Crohn’s Disease Patients Treated With Certolizumab Pegol: Multivariate and Univariate Analyses From the PRECiSE 3 Study
The American Journal of Gastroenterology2014-10-011 citations
Disease Location as a Risk Determinant for Maintenance of Remission in Crohn’s Disease Patients Treated With Certolizumab Pegol: Results of Analyses From the PRECiSE 3 Study
The American Journal of Gastroenterology2014-10-01
Disease Activity as a Predictor of Long-Term Outcomes of Treatment With Certolizumab Pegol for Active Crohn’s Disease: An Analysis of the PRECiSE 3 Study
The American Journal of Gastroenterology2014-10-01
P-145 WELCOME 54-week Open-label Extension
Inflammatory Bowel Diseases2014-01-16
Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial.
2012-05-1555 citations
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial.
2011-03-0133 citations
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
2009-11-1263 citations
Certolizumab pegol for the treatment of Crohn's disease.
2007-07-01774 citations
Maintenance therapy with certolizumab pegol for Crohn's disease.
2007-07-01709 citations